Wakamoto Pharmaceutical Co.,Ltd. (4512.T)
JPY 309.0
(6.92%)
JPY 309.0
(6.92%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.73 Billion JPY | -5.8% |
| 2022 | 3.96 Billion JPY | -9.22% |
| 2021 | 4.36 Billion JPY | -16.66% |
| 2020 | 5.24 Billion JPY | -27.09% |
| 2019 | 7.19 Billion JPY | 10.45% |
| 2018 | 6.5 Billion JPY | 5.71% |
| 2017 | 6.15 Billion JPY | 6.7% |
| 2016 | 5.77 Billion JPY | -6.83% |
| 2015 | 6.19 Billion JPY | 8.0% |
| 2014 | 5.73 Billion JPY | 4.71% |
| 2013 | 5.47 Billion JPY | 3.63% |
| 2012 | 5.28 Billion JPY | -5.29% |
| 2011 | 5.58 Billion JPY | -5.93% |
| 2010 | 5.93 Billion JPY | 3.59% |
| 2009 | 5.72 Billion JPY | -4.94% |
| 2008 | 6.02 Billion JPY | -0.02% |
| 2007 | 6.02 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.01 Billion JPY | -6.73% |
| 2023 Q1 | 932.14 Million JPY | -14.59% |
| 2023 FY | 3.73 Billion JPY | -5.8% |
| 2023 Q4 | 1.09 Billion JPY | 23.83% |
| 2023 Q3 | 881.31 Million JPY | -11.46% |
| 2023 Q2 | 995.38 Million JPY | 6.78% |
| 2022 Q3 | 921.89 Million JPY | -2.75% |
| 2022 FY | 3.96 Billion JPY | -9.22% |
| 2022 Q4 | 1.09 Billion JPY | 18.38% |
| 2022 Q2 | 947.93 Million JPY | -5.72% |
| 2022 Q1 | 1 Billion JPY | -3.67% |
| 2021 Q3 | 1.1 Billion JPY | -1.13% |
| 2021 FY | 4.36 Billion JPY | -16.66% |
| 2021 Q4 | 1.04 Billion JPY | -5.71% |
| 2021 Q1 | 1.09 Billion JPY | -15.12% |
| 2021 Q2 | 1.11 Billion JPY | 1.88% |
| 2020 Q3 | 1.21 Billion JPY | -14.83% |
| 2020 Q2 | 1.43 Billion JPY | 10.17% |
| 2020 Q1 | 1.29 Billion JPY | -13.8% |
| 2020 Q4 | 1.29 Billion JPY | 6.25% |
| 2020 FY | 5.24 Billion JPY | -27.09% |
| 2019 Q1 | 1.88 Billion JPY | -6.16% |
| 2019 FY | 7.19 Billion JPY | 10.45% |
| 2019 Q2 | 2.06 Billion JPY | 9.22% |
| 2019 Q3 | 1.73 Billion JPY | -15.81% |
| 2019 Q4 | 1.5 Billion JPY | -13.18% |
| 2018 Q4 | 2.01 Billion JPY | 29.76% |
| 2018 FY | 6.5 Billion JPY | 5.71% |
| 2018 Q1 | 1.42 Billion JPY | -4.61% |
| 2018 Q3 | 1.54 Billion JPY | 1.41% |
| 2018 Q2 | 1.52 Billion JPY | 7.59% |
| 2017 Q4 | 1.48 Billion JPY | -7.26% |
| 2017 Q2 | 1.64 Billion JPY | 15.64% |
| 2017 FY | 6.15 Billion JPY | 6.7% |
| 2017 Q1 | 1.42 Billion JPY | 0.41% |
| 2017 Q3 | 1.6 Billion JPY | -2.27% |
| 2016 FY | 5.77 Billion JPY | -6.83% |
| 2016 Q1 | 1.42 Billion JPY | -9.49% |
| 2016 Q3 | 1.44 Billion JPY | -2.57% |
| 2016 Q2 | 1.48 Billion JPY | 3.93% |
| 2016 Q4 | 1.41 Billion JPY | -2.1% |
| 2015 Q3 | 1.57 Billion JPY | 3.22% |
| 2015 Q4 | 1.57 Billion JPY | 0.42% |
| 2015 FY | 6.19 Billion JPY | 8.0% |
| 2015 Q1 | 1.52 Billion JPY | -2.45% |
| 2015 Q2 | 1.52 Billion JPY | -0.23% |
| 2014 Q4 | 1.56 Billion JPY | 13.52% |
| 2014 FY | 5.73 Billion JPY | 4.71% |
| 2014 Q3 | 1.37 Billion JPY | 2.78% |
| 2014 Q2 | 1.33 Billion JPY | -7.9% |
| 2014 Q1 | 1.45 Billion JPY | 1.1% |
| 2013 Q3 | 1.28 Billion JPY | -3.0% |
| 2013 Q4 | 1.43 Billion JPY | 11.66% |
| 2013 FY | 5.47 Billion JPY | 3.63% |
| 2013 Q1 | 1.42 Billion JPY | 5.87% |
| 2013 Q2 | 1.32 Billion JPY | -6.49% |
| 2012 Q3 | 1.25 Billion JPY | -10.41% |
| 2012 Q4 | 1.34 Billion JPY | 6.68% |
| 2012 FY | 5.28 Billion JPY | -5.29% |
| 2012 Q1 | 1.28 Billion JPY | -4.95% |
| 2012 Q2 | 1.4 Billion JPY | 9.62% |
| 2011 FY | 5.58 Billion JPY | -5.93% |
| 2011 Q1 | 1.54 Billion JPY | 9.03% |
| 2011 Q2 | 1.34 Billion JPY | -12.78% |
| 2011 Q3 | 1.34 Billion JPY | 0.45% |
| 2011 Q4 | 1.34 Billion JPY | -0.13% |
| 2010 FY | 5.93 Billion JPY | 3.59% |
| 2010 Q2 | 1.56 Billion JPY | 6.71% |
| 2010 Q1 | 1.47 Billion JPY | -0.09% |
| 2010 Q3 | 1.47 Billion JPY | -5.7% |
| 2010 Q4 | 1.41 Billion JPY | -4.54% |
| 2009 Q4 | 1.47 Billion JPY | 5.79% |
| 2009 Q1 | 1.47 Billion JPY | -4.61% |
| 2009 FY | 5.72 Billion JPY | -4.94% |
| 2009 Q2 | 1.39 Billion JPY | -5.42% |
| 2009 Q3 | 1.39 Billion JPY | -0.11% |
| 2008 Q4 | 1.54 Billion JPY | 3.44% |
| 2008 Q3 | 1.49 Billion JPY | -4.1% |
| 2008 Q2 | 1.55 Billion JPY | 0.0% |
| 2008 FY | 6.02 Billion JPY | -0.02% |
| 2007 FY | 6.02 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 91.438% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 99.857% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 99.311% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 98.109% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 94.307% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | 87.128% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 99.299% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | 29.262% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 94.322% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 91.924% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | 67.659% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | 54.612% |
| Tsumura & Co. | 48.8 Billion JPY | 92.344% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | 88.788% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | 80.875% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 94.138% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | 70.48% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 90.766% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 91.769% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | 10.119% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | 37.151% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | 28.459% |
| MedRx Co., Ltd | 959 Million JPY | -289.61% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | -30.018% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -153.141% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | -57.608% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | 84.538% |
| Sawai Group Holdings Co., Ltd. | 35.43 Billion JPY | 89.455% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -408.223% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 96.257% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | -65.524% |